First Choice Research Centers Clinical Trials
First Choice Research Centers offer clinical trials for Alzheimer’s disease, Dementia, Parkinson’s disease, Epilepsy, and other neurological disorders.
First Choice Research Center 2 Clinical Trials
AD mission Study by Eisai (Study is ongoing but closed for enrollment)
Elenbecestat is an oral BACE (beta-amyloid cleavage enzyme) inhibitor agent with a low side effect profile. MCI (mild cognitive impairment) and mild AD (Alzheimer’s disease) dementia patients. MMSE 24 and above. The age limit is 85.
BAN2401 by Eisai
BAN2401 is a humanized monoclonal antibody that targets the protofibrils of beta-amyloid before they aggregate into amyloid plaques. This phase 3 trial allows patients ages 50-90, including mild cognitive impairment and early dementia (MMSE 22-30) and is designed to have an open-label extension for 2 years or until the drug is available on the market.
For this infusion trial, patients must be able to have MRIs. Informant/study partner is needed. Patients get a free amyloid PET CT during screening for this study. Information about phase 2 results is available here: https://www.eisai.com/news/2018/news201866.html
Harmony Study by Acadia
This is a Nuplazid/Pimavanserin study for Dementia Patients with hallucinations and/or delusions ages 50-90. (Dementia-related Psychosis). ALL TYPES of Dementia are allowed and MRIs are not needed. Informant/study partner is needed.
Periscope Study by Lilly
(LMDC trial) This is for Alzheimer’s disease and MCI patients. MMSE 22 and above. This is an infusion study with anti-TAU monoclonal Antibody. Patients will require TAU PET CT and MRI brain. Ages 60-85. Informant/study partner is needed.
PRESENCE Study by Lilly
(HBEH trial). This is a Parkinson’s disease Dementia (PDD) Study. Ages 40-85. At least 2 years of Parkinson’s disease. Hoehn and Yahr Stages 1 to 4. Patients with DLB (Lewy body dementia) also qualify for the study. This is a novel dopamine D1 receptor subtype (D1PAM) positive Dopamine allosteric modulator being tested to enhance cognition in PDD.
SPARC Early Parkinson’s Disease Study
This is a novel TKI compound (K0706) that prevents the neurodegeneration induced by MPTP in animal models. Age ≥ 50 years. Diagnosed with “Clinically Probable PD”. For treatment naïve patients, with a documented onset of symptoms within three years of the Screening visit. Disease severity Hoehn & Yahr stage ≤ 2 and not expected to start dopaminergic therapy within 9 months from baseline.
First Choice Research Center 26 Clinical Trials
BAN2401 by Eisai
BAN2401 is a humanized monoclonal antibody that targets the protofibrils of beta-amyloid before they aggregate into amyloid plaques. This phase 3 trial allows patients ages 50-90, including mild cognitive impairment and early dementia (MMSE 22-30) and is designed to have an open-label extension for 2 years or until the drug is available on the market.
For this infusion trial, patients must be able to have MRIs. Informant/study partner is needed. Patients get a free amyloid PET CT during screening for this study. Information about phase 2 results is available here: https://www.fcneurology.net/services/research-centers/ban2401-study/
Hereditary Amyloid Neuropathy Research Study by Ambry Genetics Laboratories
The HAPPIN Study is research for Hereditary Amyloid Polyneuropathy Prevalence in Idiopathic Neuropathy.
Neuropathy is a common neurologic disorder whereby patients experience numbness, tingling, weakness, and unexplained pain of the extremities. Common causes include diabetes, chronic disease, cancer, HIV, and other metabolic disorders. Neuropathy leads to significant pain, weakness, and overall functional disability. If it affects the heart or autonomic system, it can also be life-threatening.
Learn more about the study here: https://www.fcneurology.net/services/research-centers/hereditary-amyloid-neuropathy-research-study/
First Choice Research Center 32 Clinical Trials
Migraine Clinical Studies:
Biohaven BHV3500-302
A phase 2/3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Zavegepant in migraine prevention.
Biohaven BHV3000-404
A phase 4 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety or Rimegepant in episodic migraine prevention with multiple dosing regimens.
Abbvie M22-418
Chronic Migraine: A phase 3 multicenter 24-week open-label study to evaluate the safety, tolerability, and efficacy of Atogepant when added to OnabotulinumtoxinA (BOTOX) for the prevention of treatment of chronic migraine.
Abbvie M21-307
Episodic Migraine: Phase 3 study of BOTOX (Botulinum Toxin Type A) for the prevention of migraine in subjects with episodic migraine.
Alzheimer's Disease Clinical Studies:
Cassava PTI-125-07
A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 52-week study evaluating the safety and efficacy of Simufilam 100mg tablets in subjects with mild-to-moderate Alzheimer’s Disease.
Eli Lilly I5T-MC-AACM
A study of donanemab versus placebo in participants at risk for cognitive and functional decline for Alzheimer’s Disease.
Multiple Sclerosis Clinical Studies:
Celgene RPC-1063-MS-001
A multicenter, longitudinal, open-label, single-arm study describing cognitive processing speed changes in relapsing multiple sclerosis subjects treated with Ozanimod (RPC-1063).
Grunenthal
This is a 1-year clinical trial, investigating Neridronic Acid in the form of an infusion for the treatment of Complex Regional Pain Syndrome. There will be 4 infusions over the course of 10 days, with the possibility of a second course of infusions at the 6-month mark. Patients must show CRPS symptoms for 2 years or less and have also failed at least 2 prior therapies.
Allergan
This is a 6-month clinical trial, investigating Atogepant for the prevention of Migraines in patients with Episodic Migraine. Patients must be 18 to 80 years of age, have 4 to 14 probable migraine headache days per month and have a migraine onset age of less than 50.
TRIAD by Avanir
This is a 12-week clinical trial, investigating d6-DM/Q for the treatment of agitation in patients with dementia of the Alzheimer’s type. Patients must be between 50 and 90 years of age and have a MMSE score of 6 to 26.
RESTORE by Lundbeck
This is a 9-month clinical trial, investigating Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension. Patients must have a documented drop of 20 mmHg in Systolic Blood Pressure, within 3 minutes of standing.
ALITHIOS by Novartis
This is a 5-year clinical trial, investigating the long-term safety and tolerability of Ofatumumab in patients with Relapsing Multiple Sclerosis. Patients must have participated in a Novartis MS trial using Ofatumumab as ALITHIOS is an open-label extension trial to its predecessor.
BRAIN by UCB
This is a 1-year clinical trial, investigating retention of patients using Brivaracetam for the treatment of epilepsy.
INSYTE by Acadia
This is a 3-year clinical trial, investigating the effectiveness of antipsychotic therapies and other treatment approaches in the management of Parkinson’s Disease Psychosis.
Genzyme
This is a 10-year clinical trial, investigating the necessary duration of monitoring in patients using Lemtrada for the treatment of Multiple Sclerosis.